Wire open Last filed Tradipitant GLP 1 vomiting trial reports 27 percent relative drop in Phase 3 RSS
Peptide Zone

Peptide medicine news,
filed as it happens.

Morning wire

Peptide medicine news, filed as it happens

Peptide Zone is a news wire for peptide medicines such as GLP-1 drugs, amylin analogues and peptide vaccines. Each story covers one regulator decision, trial readout, industry deal or safety review, names its primary source and says what comes next. Nothing here is medical advice. About the newsroom

UrgentTRLNews

Tradipitant GLP 1 vomiting trial reports 27 percent relative drop in Phase 3

Vanda Pharmaceuticals says its motion sickness drug Nereus lowered vomiting after a forced semaglutide dose in Phase 3, though the effect was smaller than in Phase 2 and full safety data are not public.

WASHINGTON

27%Relative reduction in any vomiting with Nereus versus placebo in Phase 3 Study 3601
  1. What's newVanda Pharmaceuticals said its oral NK1 blocker Nereus (tradipitant) met both main goals in Phase 3 Study 3601, with 43.0% vomiting on the drug against 58.5% on placebo after an untitrated semaglutide dose.
  2. Why it mattersNausea and vomiting are among the reasons people stop GLP 1 drugs, the company said. The Phase 3 effect was smaller than the 50% relative cut seen in Phase 2, and the trial did not measure whether people stayed on treatment.
  3. What's nextVanda plans to discuss the data with the FDA and file an sNDA, with no date given. Full results, safety tables and data in people titrating normally have not been released.

Latest on the wire

Full wire

The 60-second briefing

Five things filed most recently

  1. SAF · 28 Oct 2026A News-Medical review published 26 October summarises research on GLP 1 drugs and eating disorders, finding early but inconsistent signals in binge eating disorder and no evidence the drugs cause anorexia nervosa.
  2. IND · 27 Oct 2026The 2026 KFF Employer Health Benefits Survey finds GLP 1 coverage for weight loss flat at 18% of firms with 200 or more workers, with 40% of covering firms now requiring a lifestyle program or counselling.
  3. REG · 27 Oct 2026WADA left the status of GLP 1 receptor agonists unchanged in its 2027 Prohibited List, so semaglutide and tirzepatide stay permitted for athletes and remain on the Monitoring Program.
  4. SAF · 27 Oct 2026University of Queensland researchers say people who inject online peptides need needle program access and basic safety advice, and they set out five safety basics.
  5. TRL · 27 Oct 2026Dong-A ST presented ex vivo skin and animal data on a topical formulation of icotrokinra, the oral IL 23 receptor blocking peptide approved by the FDA in March 2026.

By the numbers

The one figure each story turns on.

28.7%average weight loss on the highest dose after 68 weeks TRL · 11 DEC · Retatrutide posts the largest average weight loss yet in a phase 3 trial 62.9%of treated patients saw liver inflammation resolve without fibrosis worsening, vs 34.3% on placebo REG · 15 AUG · Wegovy gets accelerated approval for fatty-liver disease with scarring 20.2%average weight loss on tirzepatide vs 13.7% on semaglutide after 72 weeks TRL · 11 MAY · Head to head, tirzepatide beats semaglutide on weight loss 1stprescription drug approved to treat obstructive sleep apnea in adults with obesity REG · 20 DEC · FDA clears tirzepatide as the first medicine for obstructive sleep apnea 6 of 7Peptides the FDA compounding advisory committee backed for the 503A Bulks List in July 2026 SAF · 26 OCT · JAMA Viewpoint warns peptide compounding vote threatens the FDA approval system 4 divisionsMinistry divisions that co-signed the October 14 notice recirculating the GLP 1 appropriate use rules SAF · 25 OCT · Japan reissues GLP 1 appropriate use notice with a ketosis warning for slimming use

Threads we are following

Storylines that span months. Each dot is a story, placed by date.

Thread · 4 stories

Copies, risks and rules

What can people legally get, and how do regulators react when demand outruns supply?

Dec 2024Oct 2026

  • 06 JUNEU safety committee adds a rare eye condition to semaglutide warnings
  • 21 FEBSemaglutide shortage declared over, starting the clock on compounded copies

Thread · 6 stories

The incretin race

Who ends up with the most weight loss, the fewest side effects and the easiest dosing?

Dec 2024Oct 2026

  • 07 AUGThe weight-loss pill that is not a peptide posts its first obesity readout
  • 12 MARRoche buys into petrelintide in a bet that amylin is the next act

Thread · 4 stories

Beyond the scale

Which organ benefits hold up in outcome trials, and which do not?

Dec 2024Oct 2026

  • 24 NOVSemaglutide fails to slow Alzheimer's in two large trials
  • 28 JANSemaglutide wins a kidney label after the FLOW outcome trial

Desk fronts

REGRegulators8
TRLTrials17
INDIndustry5
SAFSafety12
EXPExplainers2

Where this news came from

Primary source type of every story on the wire. How we label sources

  • Regulator11
  • Journal9
  • Company release11
  • Conference5
  • Our newsroom8